Ultrastructural organization of hemomicrocirculatory bed of the lungs affected by Doxorubicin

  • L.M. Zaiats Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
  • O.O. Yankiv National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • I.V. Gunas National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • O.M. Shapoval National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • O.V. Shypitsina National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: lungs, hemomicrocirculatory bed, Doxorubicin.


One of the most effective anticancer drugs for breast cancer, lymphoma, soft tissue sarcoma, leukemia, some solid tumors is Doxorubicin. However, its antitumor effect directly correlates with the dose-dependent manifestation of toxicity to healthy tissues and body systems. The purpose of the study is to study the dynamics of ultrastructural changes of the hemomicrocirculatory bed under the influence of Doxorubicin. Animals were divided into 3 groups: I – intact rats (n=10); II – control (n=20); III – rats with Doxorubicin model (n=40). Doxorubicin was administered intraperitoneally at a dose of 5 mg/kg body weight once a week for 4 weeks. An animal control group was intraperitoneally injected with an equivalent volume of saline. Pulmonary tissue sampling for electron microscopic examination was performed under thiopental anesthesia 7, 14, 21, 28 days after the start of the experiment. Pieces of pulmonary tissue were fixed in 2.5% glutaraldehyde followed by fixation in 1% osmium tetroxide. After dehydration, the material was poured into araldite-epon. The sections obtained on a “Tesla BS-490” ultramicrotome were examined in an electron microscope “PEM-125K”. It is established that within 7 days after the first injection of Doxorubicin in the lungs changes in the structural organization of the hemomicrocapillary bed and the disturbance of blood rheological properties are determined, as evidenced by the excessive accumulation of neutrophils in the hemocapillaries, their adhesion and aggregation. With the extension of the study period (14-28 days) there is a progressive disturbance of the submicroscopic structure of hemocapillaries of the alveolar wall and marked changes in the rheological properties of blood. In endothelial cells, swelling phenomena with organelle disorganization are determined, and in some areas there is a desquamation of endothelial cells into the lumen of the hemocapillaries with basal membrane exposures. In the lumen of the microvessels, red blood cells and leuco-platelet aggregates are noted. Thus, the introduction of Doxorubicin leads to pronounced submicroscopic changes in the hemomicrocirculatory bed. Violation of the ultrastructural organization of the hemomicrocirculatory bed of the lungs is determined after 7 days after the start of the study.


[1] Bazykov, I. A., Beier, E. V., Lukynova, V. V., & Maltsev, A. N. (2015). Comparative evaluation of the acute toxicity of Doxorubicin and its niosomal form. Medical Bulletin of the North Caucasus, 10(4(38)), 403-406.

[2] Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010). Doxorubicin cardiomyopathy. Cardiology, 115(2), 155-162. doi: 10.1159/000265166

[3] Diamond, O. M., Turgeman, O., & Blumenfeld, Z. (2015). Minimizing the Doxorubicin-Induced gonadotoxicity by sphingosine-1-phosphate analogue FTY720. Am. J. Clin. Exp. Obstet. Gynecol., 2(1), 24-33.

[4] Fernandez-Chas, M., Curtis, M. J., & Niederer, S. A. (2018). Mechanism of Doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model. British Journal of Pharmacology, 175(5), 763-781. doi: 10.1111/bph.14104

[5] Haina, Zh. M., Kosuba, R. B., & Yaremii, I. M. (2012). Corrective effect of mildronate on the performance of oxidant-antioxidant equilibrium in rats against toxic Doxorubicin. Medical Chemistry, 1(14), 56-59.

[6] He, H., Liu, C., Wu, Y., Zhang, X., Fan, J., & Cao, Y. (2018). A multiscale physiologically-based pharmacokinetic model for Doxorubicin to explore its mechanisms of cytotoxicity and cardiotoxicity in human physiological contexts. Pharmaceutical research, 35(9), 174. doi: 10.1007/sl 1095-018-2456-8

[7] Hordiienko, Yu. A., Baklanova, Ya., Kovalenko, M. V., Stechenko, L. M., Shevtsova, A. I., & Ushakova, G. O. (2012). Changes in physiological and biochemical parameters in rats with Doxorubicin-induced cardiopathy against the use of antioxidant drugs. Animal biology, 14(1-2), 74-79.

[8] Hozayen, W. G., Abou Seif, H. S., & Amin, S. (2014). Protective effects of ruitn and/or hesperidin against Doxorubicin-induced hepatotoxicity. Int. J. Clin. Nutr., 2(1), 11-17. doi: 10.12691/ijcn-2-1-2

[9] Kolotova, O. V., Fedorova, E. P., Ermolaeva, L. A., & Churyn, A. A. (2008). The ability to correct the toxic effects of paclitaxel. Siberian Oncology Journal, (1), 66-68.

[10] Kоbylinska, L. I., Havrylyuk, D. Y., Mitina, N. E., Zаichenko, A. S., Lesyk, R. B., Zіmenkovsky, B. S., & Stoika, R. S. (2016). Biochemical indicators of nephrotoxicity in blood serum of rats treated with novel 4-thiazolidinone derivatives or their complexes with polyethylene glycol-containing nanoscale polymeric carrier. The Ukrainian Biochemical Journal, 88(1), 51-60. doi: 10.15407/ubj88.01.051

[11] Linnyk, O. O., Drevytska, T. I., Tarasova, K. V., Portnichenko, G. V., Dosenko, V. E., & Mankovska, I. M. (2016). Impairment of contractile activity of cardiomyocytes under the action of Doxorubicin. Physiological Journal, 6(62), 65-71.

[12] Linnyk, O. O., Honchar, O. O., Nosar, V. I., Drevytska, T. I., Kovalov, O. M., & Mankovska, I. M. (2017). Effect of curcumin on mitochondrial function of cardiomyocytes in Doxorubicin-induced oxidative stress. Physiological Journal, 1(63), 10-16.

[13] Luu, A. Z., Chowdhury, B., Al-Omran, M., Teoh, H., Hess, D. A., & Verma, S. (2018). Role of endothelium in Doxorubicin-induced cardiomyopathy. JACC: Basic to Translational Science, 3(6), 861-870. doi: 10.1016/j.jacbts.2018.06.005

[14] McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017). Anthracycline chemotherapy and cardiotoxicity. Cardiovascular Drugs and Therapy, 31(1), 63-75. doi: 10.1007/sl0557-016-6711-0

[15] Pakryshen, S. V., & Mokhort, M. A. (2013). Toxicodynamics of Doxorubicin (morphological study). Modern Problems of Toxicology, (1-2), 81-85.

[16] Ruggeri, C., Gioffré, S., Achilli, F., Colombo, G. I., & D’Alessandra, Y. (2018). Role of microRNAs in Doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients. Heart Failure Reviews, 23(1), 109-122. doi: 10.1007/s 10741 -017-9653-0

[17] Shchepotyn, I. (2013). What do we know about cancer? Pharmacist Practitioner, 2, 8.

[18] Shevchuk, O. O., Volska, A. S., Yaremchuk, O. Z., Kurylo, K. I., Bardakhivska, K. I., Nikolaev, V. G., & Posokhova, K. A. (2019). Prooxidant-antioxidant balance in rats against subchronic Doxorubicin toxicity and the use of enterosorption and filgrastim (literature review and results of own studies). Medical and Clinical Chemistry, 3(21), 13-22. doi: 10.11603/mcch.2410-681X.2019.v.i3.10555

[19] Shushanov, S. S., & Kravtsova, T. A. (2013). In vitro cytotoxic effect of Doxorubicin on human multiple myeloma cells. Bulletin of Experimental Biology and Medicine, 155(2), 195-200.

[20] Todor, I. M., Lukianova, N. Yu., Tymovska, Yu. O., Pivniuk, V. M., & Chekhun, V. F. (2013). Influence of Doxorubicin in liposomal form on tumors with phenotype of drug resistance. Oncology, 4(15), 279-285.

[21] Volkova, M., & Russell, R. (2011). Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Current Cardiology Reviews, 7(4), 214-220. doi: 10.2174/157340311799960645

[22] Zupanets, I. A., Vietrova, K. V., Sakharova, T. S., & Torianik, E. L. (2013). Possibilities of correction of toxic effects of anticancer antibiotic Doxorubicin by derivatives of glucose mine and their combinations. Ukrainian Biopharmaceutical Journal, 4(27), 87-92.
How to Cite
Zaiats, L., Yankiv, O., Gunas, I., Shapoval, O., & Shypitsina, O. (2019). Ultrastructural organization of hemomicrocirculatory bed of the lungs affected by Doxorubicin. Reports of Morphology, 25(3), 58-62. https://doi.org/https://doi.org/10.31393/morphology-journal-2019-25(3)-10

Most read articles by the same author(s)